AbbVie   1Q Revenues: $4.6 billion (+5%) 1Q Earnings: $980 million (+1%) Comments: Growth in the quarter was primarily driven by HUMIRA sales, up 18% to $2.6 billion, as well as key products including Synthroid (up 31% to $157 million), Creon (up 18% to $107 million) and Duodopa (up 32% to $52 million).Synagis sales were $324 million, up 3%. AndroGel sales were $254 million, up 6%. Kaletra sales were down 11% to $195 million. Niaspan and TriCor/Trilipix dropped 75% and 82% to $47 and $23 milli...